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Analysis of the ATR-Chk1 and ATM-
Chk2 pathways in male breast 
cancer revealed the prognostic 
significance of ATR expression
Anna Di Benedetto1, Cristiana Ercolani1, Marcella Mottolese1, Francesca Sperati2, Laura 
Pizzuti3, Patrizia Vici3, Irene Terrenato2, Abeer M. Shaaban4, Matthew P. Humphries5,  
Luigi Di Lauro3, Maddalena Barba  3,6, Ilio Vitale6,7, Gennaro Ciliberto6, Valerie Speirs  5, 
Ruggero De Maria8 & Marcello Maugeri-Saccà3,6
The ATR-Chk1 and ATM-Chk2 pathways are central in DNA damage repair (DDR) and their over-
activation may confer aggressive molecular features, being an adaptive response to endogenous DNA 
damage and oncogene-induced replication stress. Herein we investigated the ATR-Chk1 and ATM-Chk2 
signalings in male breast cancer (MBC). The expression of DDR kinases (pATR, pATM, pChk1, pChk2, 
and pWee1) and DNA damage markers (pRPA32 and γ-H2AX) was evaluated by immunohistochemistry 
in 289 MBC samples to assess their association. Survival analyses were carried out in 112 patients. 
Survival curves were estimated with the Kaplan-Meier method and compared by log-rank test. Cox 
proportional regression models were generated to identify variables impacting survival outcomes. The 
expression of pATR conferred poorer survival outcomes (log rank p = 0.013, p = 0.007 and p = 0.010 
for overall, 15- and 10-year survival, respectively). Multivariate Cox models of 10-year survival and 
overall indicated that pATR expression, alone or combined with pChk2, was an independent predictor 
of adverse outcomes (10-year survival: pATR: HR 2.74, 95% CI: 1.23–6.10; pATR/pChk2: HR 2.92, 95% 
CI: 1.35–6.33; overall survival: pATR: HR 2.58, 95% CI: 1.20–5.53; pATR/pChk2: HR 2.89, 95% CI: 1.37–
6.12). Overall, the ATR/ATM-initiated molecular cascade seems to be active in a fraction of MBC patients 
and may represent a negative prognostic factor.
Male breast cancer (MBC) is a rare neoplasm that shares similarities with post-menopausal breast cancer1, 2. 
Indeed, MBC is a disease of elderly men, which frequently expresses steroid receptors, namely the estrogen recep-
tor (ER), progesterone receptor (PgR) and androgen receptor (AR)1, 3. The hormone-dependent nature of MBC 
is exploited for therapeutic purposes, since hormone therapies including tamoxifen4, aromatase inhibitors5–7, 
fulvestrant8, GnRH analogues9, and antiandrogens10 have shown antitumor activity, albeit in retrospective studies.
Impressive advancements have been made in the molecular characterization of tumours over the last dec-
ade. As a result, most common tumors were stratified into a number of subtypes, each characterized by spe-
cific genomic alterations and deregulated pathways. Although the rarity of MBC has hindered comprehensive 
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characterization efforts, initial clues on the nature of its genetic abnormalities are beginning to be elucidated11–17. 
Recently, massive parallel sequencing of 241 genes frequently mutated in female breast cancer has been applied 
to a series of 59 MBC samples, reporting a significant enrichment for mutations/copy number variations in DNA 
repair–related genes17. Results suggest that, in MBC, the DNA damage response (DDR) machinery is targeted by 
genetic abnormalities at multiple levels, including central players of the apoptotic response (e.g. TP53), effectors/
mediators of the DDR (e.g. CHEK1, PALB2, and BRCA2), and mechanisms fueling oncogene-induced replication 
stress (e.g. MYC amplification). In this small-sized case series, a suggestion toward inferior survival outcomes was 
observed in patients whose tumors harbored DDR alterations.
The DNA damage response (DDR) is a sophisticated molecular network deputed to maintain genomic sta-
bility by correcting DNA damage or eliminating cells whose damage overwhelms repair capabilities18. The DDR 
encompasses a number of pathways that are activated by the presence of single-stranded DNA (ssDNA), DNA 
single- and double-strand breaks (SSBs and DSBs, respectively). Schematically, DDR pathways can be grouped 
into: (i) cell cycle checkpoints that halt the progression of the cell cycle, (ii) DNA repair mechanisms that remove 
DNA lesions, (iii) DNA damage tolerance processes that enable cells to withstand persisting lesions in the absence 
of repair, and (iv) cell death pathways that eliminate irremediably damaged cells19.
The ataxia telangiectasia mutated (ATM) kinase is activated upon the onset of DSBs, whereas the ataxia 
telangiectasia and Rad3-related protein (ATR) recognizes ssDNA and SSBs20, 21. Upon their recruitment to 
DNA damage sites, ATM and ATR activate the Checkpoint Kinase 2 (Chk2) and Checkpoint kinase 1 (Chk1), 
respectively, even though an extensive communication exists between the two signaling avenues. Overall, the 
AMT-Chk2 and ATR-Chk1 pathways, together with the Wee1-like protein kinase (Wee1) that is activated by 
Chk1, are crucial for determining cell fate upon genotoxic injuries, being central in the G1-S, intra-S and G2-M 
cell cycle checkpoints20, 21.
Our previous results, both at the preclinical and clinical level, suggest that abnormal DDR activation is linked 
to suboptimal efficacy of chemotherapy22–25. Herein we hypothesized that over-activation of ATM-ATR-initiated 
signaling may configure a subset of MBC endowed with more aggressive molecular traits, assuming that this 
process reflects an underlying genetic portrait dominated by deregulated cell cycle control systems (e.g. TP53 
mutations) and elevated levels of oncogene-induced replication stress (e.g. MYC amplification)26, 27. To test this 
hypothesis, a large series of MBC samples were immunostained for evaluating the expression of central DDR 
kinases, namely phosphorylated (activated) ATR (pATR), ATM (pATM), Chk1 (pChk1), Chk2 (pChk2), and 
Wee1 (pWee1). The panel of candidate biomarkers was completed by the assessment of the DNA DSB marker 
phosphorylated H2A Histone Family Member X (γ-H2AX) and the replication stress marker phosphorylated 
replication protein A2 (pRPA2, best known as pRPA32).
Results
Characteristics of the patients and expression pattern of DDR biomarkers. Baseline charac-
teristics of MBC patients whose biological samples were immunostained (N = 289) are summarized in Table 1, 
together with the characteristics of patients who met the eligibility criteria for the analysis of survival outcomes 
(N = 112). The flow diagram illustrating patients’ selection process is detailed in Fig. 1. Representative immu-
nohistochemical staining is presented in Fig. 2. We first investigated whether the expression pattern of DDR 
biomarkers was consistent with the hypothesis of activated ATR-ATM signaling in MBC. As presented in Fig. 3, a 
significant association (co-expression) was observed between many of the investigated markers. Further enforc-
ing our hypothesis, we recorded multiple significant correlations when DDR markers were analyzed as contin-
uous variables (percentage of nuclear-expressing tumor cells), as presented in Supplementary Table 1. When 
evaluating the relationship between DDR markers and standard clinical, pathological and molecular features 
(detailed in Table 1), the only significant associations were between pChk1 and age (Chi2 p = 0.046) and pATR 
and age (Chi2 p = 0.048). Indeed, both biomarkers were more expressed in tumors from older patients (data 
available upon request).
DDR biomarkers and survival outcomes. Patients whose tumors expressed pATR (N = 63/112, 56.3%) 
had poorer survival outcomes compared with their negative counterparts (log rank p = 0.013, p = 0.007 and 
p = 0.010 for OS, 15- and 10-year survival, respectively, Fig. 4 panel A). The combined expression of pATR and 
pChk2 (N = 21/112, 18.8%) was associated with similar adverse survival outcomes than pATR alone, with a trend 
toward statistical significance for 5-year survival (log rank p = 0.058, Fig. 4 panel B). A model of triple-positivity 
(pATR/pChk2/pATM, N = 10/112, 8.9%) was fully significant also for 5-year survival (log rank p = 0.048), 
although the number of patients falling into this molecular group is limited (data available upon request).
Univariate Cox regression analyses (Table 2) carried out for identifying factors impacting 10-year survival 
confirmed the adverse prognostic significance of pATR, pATR/pChk2 and pATR/pChk2/pATM (pATR: HR 2.71, 
95% CI: 1.22–5.99, p = 0.014; pATR/pChk2: HR 2.67, 95% CI: 1.27–5.62, p = 0.010; pATR/pChk2/pATM: HR 
3.76, 95% CI: 1.69–8.35, p = 0.001). Multivariate Cox regression models (Table 2) generated by adjusting for 
other plausible predictors of the outcome of interest confirmed these results (pATR: HR 2.74, 95% CI: 1.23–6.10, 
p = 0.014; pATR/pChk2: HR 2.92, 95% CI: 1.35–6.33, p = 0.007; pATR/pChk2/pATM: HR 4.76, 95% CI: 2.05–
11.04, p < 0.001). As shown in Table 3, uni- and multivariate Cox regression models for OS yielded comparable 
results (pATR multivariate Cox: HR 2.58, 95% CI: 1.20–5.53, p = 0.015; pATR/pChk2 multivariate Cox: HR 2.89, 
95% CI: 1.37–6.12, p = 0.005; pATR/pChk2/pATM multivariate Cox: HR 4.71, 95% CI: 2.04–10.86, p < 0.001). 
A sensitivity analysis carried out on a subset of 99 patients with available data on Ki-67 that considered Ki-67 
among the variables of interest, confirmed the adverse impact of DDR markers on 10-year survival (pATR multi-
variate Cox: HR 2.65, 95% CI:1.15–6.12, p = 0.023; pATR/pChk2 multivariate Cox: HR: 3.24, 95% CI: 1.40–7.47, 
p = 0.006; pATR/pChk2/pATM multivariate Cox: HR 5.16, 95% CI: 2.07–12.83, p < 0.001) (Table 4). Finally, 
in subgroup analysis, pATR expression and the pATR/pChk2 co-expression model were associated with an 
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increased risk of death within a 10-year timeframe in the subgroup of patients with elevated Ki-67 levels and with 
node-positive disease (Supplementary Figure 1), although to a borderline significant extent. In these subgroups, 
the pATR/pChk2/pATM model was fully significant in the subset of patients with elevated Ki-67 levels in their 
tumors and with nodal involvement (HR 7.44, 95% CI: 2.18–25.46, p = 0.001; and HR 9.66, 95% CI 2.75–33.87, 
p < 0.001, respectively; data available upon request).
Discussion
In the present study, we investigated whether core components of the DDR are involved in MBC, and 
whether this process translates into adverse survival outcomes. Overall, our pathway-level analysis suggests 
that a portion of MBC carries activation of the molecular cascade safeguarding the genome and the trans-
mission of an unaltered genetic code to daughter cells. Furthermore, we identified elevated pATR expres-
sion, both alone or with pChk2 and eventually in a triple model that considers pATM, as a plausible negative 
prognostic factor for MBC patients.
The present collection of MBC samples was already exploited for translational studies investigating stem cell 
and metabolic pathways28–30. As discussed earlier, the rarity of the disease and the correlated need for collecting 
samples across multiple countries and in a wide time window (1983–2009) resulted in the partial unavailability 
of some information. The unestablished cause of death for all the patients analyzed (37 deaths, 13 cancer-related 
deaths, 24 deaths from unknown cause), together with fragmented data on adjuvant therapy, need to be carefully 
considered. Aware of these intrinsic limitations, we analyzed the impact of DDR markers on survival outcomes at 
different time-points, deducing that this approach may soften the partial unavailability of cancer-specific events, 
especially in consideration of the fact that an elderly patient’ population was the focus of the present investigation. 
Regarding adjuvant therapy, the data gathered indicate a therapeutic approach that is consistent with current 
recommendations. Indeed, tamoxifen is the therapy of choice in the adjuvant setting, despite the high discontinu-
ation rate in MBC patients (e.g. sexual dysfunction and thromboembolic events) legitimates the use of aromatase 
inhibitors31.
Nevertheless, our study offers some intriguing clues on the functional status of a commonly deregulated 
pathway in cancer. First, the co-expression pattern observed for many biomarkers indicates activation of 
upstream branches of the DDR in a subset of MBC, a process supposedly correlated with the need for 
compensating genetic defects that deregulate, and overall accelerate, the transition between the various 
phases of the cell cycle and that hinder the apoptotic response. Second, our data point to the machinery 
that senses the presence of ssDNA and SSBs as an adverse prognostic factor for these patients, plausibly 
mirroring the replication stress imposed by the constitutive activation of oncogene involved in cell pro-
liferation26. Interestingly, the negative prognostic significance of pATR expression was enhanced by the 
concomitant expression of pChk2 (and also pATM), suggesting a communication between the ATR-Chk1 
and ATM-Chk2 pathways. Historically, these signals were thought to act in parallel with partly overlapping 
functions. This view changed over time, and now we know that they have non-redundant functions in the 
DDR cascade32. Third, ATM/ATR-initiated signal is required for an array of repair pathways, spanning from 
non-homologous end joining (NHEJ), homologous recombination, nucleotide excision repair, interstrand 
Characteristics Overall population (N = 289)
Population included in 
survival analyses (N = 112)
Age at diagnosis
Median (min-
max) [IQ range] 66.8 (30–97) [58–76] 66.5 (34–89) [58.5–75]
Not Available 54 6
Histology N(%)
IDC/ILC 218 (75.4) 92 (82.1)
Other 53 (19.6)* 20 (17.9)**
Not Available 17 (5.0) —
Grade N(%)
G1–2 149 (51.6) 65 (58.0)
G3 115 (39.8) 47 (42.0)
Not Available 25 (8.6) —
Nodal status N(%)
Negative 93 (32.2) 39 (34.8)
Positive 105 (36.3) 52 (46.4)
Not Available 91 (31.5) 21 (18.8)
Hormone Receptors N(%)
ER+/PgR+ 221 (76.5) 91 (81.2)
Other 37 (12.8) 21 (18.8)
Not Available 31 (10.7) —
Ki-67 N(%)
Low (<14%) 116 (40.1) 55 (49.1)
High (≥14%) 67 (23.2) 44 (39.3)
Not Available 106 (36.7) 13 (11.6)
Table 1. Baseline characteristics of MBC patients included in this study. *10 Adenocarcinoma, 5 Intraductal 
papillary carcinoma, 10 Papillary carcinoma, 11 Mucinous carcinoma, 5 Ductal carcinoma in situ, 6 Mixed, 1 
Medullary, 2 Micropapillary, 2 Cribiform, 1 Tubular. **3 Adenocarcinoma, 4 Intraductal papillary carcinoma, 
6 Papillary carcinoma, 1 Mucinous carcinoma, 1 Mixed, 1 Medullary, 2 Micropapillary, 1 Cribiform, 1 Tubular. 
Abbreviations: IDC: Invasive Ductal Carcinoma, ILC: Invasive Lobular Carcinoma.
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crosslink (ICL) repair and replication fork stability33. Consistently with the complexity of the molecular network 
initiated by ATR and ATM, hundreds of proteins are phosphorylated in an ATM/ATR-dependent manner34. In 
consideration of the complexity of the DDR, we decided to examine core pathway components acting upstream 
the DDR cascade and coordinating the cellular response upon DNA damage. Importantly, the DDR kinases 
herein evaluated are potentially targetable with compounds that have already entered early phases of clinical 
development35, 36, and the significance of their expression may be a molecular trait MBC shares with female breast 
cancer37, 38.
The long-term strategy we envision for streamlining the development of DDR-linked biomarkers relies 
on a more exhaustive characterization of the pathway, which takes into account the origin of DNA damage 
in cancer. The genome of eukaryotic cells is susceptible to a variety of endogenous and exogenous cues, and 
this process is greatly intensified upon malignant transformation. A number of intertwined factors account 
for this including: (i) changes in cellular bioenergetics (metabolic reprogramming) that lead to an elevated 
production of byproducts, such as reactive oxygen species, capable of damaging the DNA39, (ii) activating 
mutations in oncogenes that accelerate cellular proliferation consequently resulting in replication stress 
(stalled or collapsed replication forks)26, and (iii) loss-of-function mutations in genes that restrain cellular 
proliferation27. All these conditions require a compensatory response to avoid that damaged cells embark 
into a defective, potentially catastrophic, mitosis. Over-activation of the ATM-Chk2 and ATR-Chk1 path-
ways was identified as a strategy neoplastic cells exploit to counteract the excess of DNA-damaging insults 
they are exposed. Consistently, the pharmacological targeting of DDR kinases was conceived as a syntheti-
cally lethal therapeutic approach for tumors carrying a defective G1-S transition machinery (TP53 defects) 
Figure 1. Flow diagram of the patients’ selection process.
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or characterized by elevated levels of replication stress (MYC amplification)40, 41. On this premise, we hypoth-
esize that a deeper characterization of the DDR, envisioning the simultaneous assessment of the ATM-ATR 
cascade together with mutations/copy number variations in genes that, at the protein level, participate in the 
DDR response may accelerate the development of DDR biomarkers. For instance, BRCA2 mutations or rear-
rangements and, to a lower extent, BRCA1 mutations have been described in MBC42. BRCA1 and BRCA2 
encode for two proteins that are central in the repair of DSBs by homologous recombination, being therefore 
intimately tied to ATR and ATM36. Remarkably, beyond the established sensitivity of BRCA1/2-mutated tum-
ors to inhibitors of poly(ADP-ribose)-polymerase (PARP), BRCA1- deficient cells were found to be sensitive 
to ATM inhibition43. Collectively, a series of evidence highlight the potential of DDR-targeting agents for the 
treatment of MBC patients.
Overall, our results suggest that the molecular network that senses, signals and amplifies the presence of 
genetic lesions is active in MBC, and patients whose tumors display this molecular portrait may have adverse 
Figure 2. Representative examples of immunohistochemical expression of pATR, pChk1, pWee1, pRPA32, 
pATM, pChk2 and γ-H2AX in three male breast cancer patients (A,B,C). Panels a–d show a sample with 
nuclear expression of pATR, pCHK1, pWEE1 and pRPA32 (A). Panels e–g show a sample with nuclear 
expression of pATM, pCHK2 and γ-H2AX (B). Panels h–l show a sample with nuclear expression of pATM, 
pCHK2 and pATR (C). Slide magnification ×40, inset magnification ×10. Scale bar 30 μm.
Figure 3. OncoPrint showing the associations between DDR-related biomarkers in male breast cancer. 
Statistically significant or borderline significant associations are reported.
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survival outcomes. A larger characterization of the DDR is warranted to obtain more accurate information on 
how deregulation of this complex molecular network affects the prognosis, and in future perspective treatment, 
of MBC patients.
Material and Methods
Study Participants. Tissue microarrays (TMAs) including samples from 289 histologically confirmed 
MBC patients were immunohistochemically characterized for evaluating the expression of five DDR kinases 
(pATR, pATM, pChk1, pChk2 and pWee1) and two DNA damage markers (pRPA32 and γ-H2AX). The rela-
tionship between the biomarkers of interest was assessed in the entire cohort (N = 289), whereas their prognostic 
significance was evaluated in 112 patients based on the following criteria: (i) available information on survival 
outcomes, and (ii) complete data pertinent to the investigated markers. Given that data related to Ki-67 levels 
and nodal status were available for 99 and 91 patients, respectively, these subsets were independently analyzed. 
Information related to adjuvant therapy were available for 25 patients only (tamoxifen: N = 19; anastrozole: N = 5; 
no post-surgical therapy: N = 1). This study was conducted in accordance with the Declaration of Helsinki and 
approved by the Institutional Review Board of the “Regina Elena” National Cancer Institute of Rome and by the 
Leeds (East) Research Ethics Committee (06/Q1205/156). Written informed consent was not required as samples 
were anonymised to the research team3.
Figure 4. Kaplan-Meier survival curves comparing (A) pATR-positive and pATR-negative cases, and (B) 
pATR/pChk2-positive and single-positive/double-negative tumors (N = 112).
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Immunohistochemistry. TMAs were built from formalin-fixed paraffin-embedded (FFPE) material3. The 
immunohistochemical assessment of DDR markers was carried out in FFPE tissues using the following anti-
bodies: anti-phospho-H2AX (Ser139) (clone JBW301) mouse monoclonal antibody (MAb) (Upstate) at the 
dilution of 1:500 (pH 8), anti-phospho-ATM (Ser1981) (clone 7C10D8) mouse MAb (Rockland) at the dilu-
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pATR Pos vs Neg 2.71 (1.22–5.99) 0.014
2.74 
(1.23–6.10) 0.014 — — — —
pATR/pChk2 Pos vs Neg 2.67 (1.27–5.62) 0.010 — —
2.92 
(1.35–6.33) 0.007 — —
pATR/pChk2/pATM Pos vs Neg 3.76 (1.69–8.35) 0.001 — —
4.76 
(2.05–11.04) <0.001
Table 2. Univariate and multivariate Cox regression models for 10-year survival (N = 112). §Adjusted for: 









HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value





























pATR Pos vs Neg 2.52 (1.18–5.37) 0.017
2.58 
(1.20–5.53) 0.015 — — — —
pATR/pChk2 Pos vs Neg 2.67 (1.31–5.46) 0.007 — —
2.89 
(1.37–6.12) 0.005 — —
pATR/pChk2/pATM Pos vs Neg 3.76 (1.69–8.35) 0.001 — — — —
4.71 
(2.04–10.86) <0.001
Table 3. Univariate and multivariate Cox regression models for overall survival (N = 112). §Adjusted for: 









HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value




































pATR Pos vs Neg 2.45 (1.08–5.57) 0.033
2.65 
(1.15–6.12) 0.023 — — — —
pATR/pChk2 Pos vs Neg 2.91 (1.31–6.45) 0.009 — —
3.24 
(1.40–7.47) 0.006 — —
pATR/pChk2/pATM Pos vs Neg 4.08 (1.73–9.62) 0.001 — — — —
5.16 
(2.07–12.83) <0.001
Table 4. Univariate and multivariate Cox regression models for 10-year survival in patients with available 
information on Ki-67 levels (N = 99). §Adjusted for: Histology, Grade, Hormone Receptor Status, Ki67.
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of 1:200 (pH 6), anti-phospho-ATR (Ser 428) (clone EPR2184) rabbit MAb (Abcam) at the dilution of 1:100 
(pH 6), anti-phospho-Chk1 (Ser345) (clone 133D3) rabbit MAb (Cell Signaling) at the dilution of 1:150 (pH 
6), anti-phospho-Wee1 (Ser642) (clone D47G5) rabbit MAb (Cell Signaling) at the dilution of 1:100 (pH 8), 
anti-phospho-RPA32 (Ser4/Ser8) rabbit polyclonal antibody (Bethyl) at the dilution of 1:100 (pH 6).
Positive and negative cases were classified consistently with the method exploited in our previous studies23, 24. 
DNA damage markers (γ-H2AX and pRPA32) were classified as high and low/negative using the median score 
of all tumors as the cut-off points, whereas DDR kinases were classified as positive when ≥10% of the neoplastic 
cells displayed a distinct nuclear immunoreactivity of any intensity. Hormone receptor immunoreactivity was 
scored using the Allred system and considered positive when >23. Immunoreactivity was evaluated by two inves-
tigators (ADB and CE) blinded to baseline patient characteristics and treatment outcomes, and discordant cases 
were reviewed by a third observer (MM).
Statistical analysis. The relationship between DDR markers was assessed with the Pearson’s Chi-squared 
test of independence (2-tailed) when they were analyzed as categorical variables. Correlations were assessed by 
Pearson’s correlation test for continuous variables (percentage of nuclear-expressing tumor cells). Overall sur-
vival (OS) was calculated as the time elapsing from diagnosis to death due to any cause. Five-, 10- and 15-year 
survival were calculated as the time from diagnosis to death due to any cause within a 5-, 10- and 15-year time-
frame, respectively. Survival curves were generated by the Kaplan-Meier product-limit method and compared by 
log-rank test. Variables potentially affecting 10-year survival and OS were verified in uni- and multivariate Cox 
proportional hazard models. Statistical significance was set at p < 0.05. Statistical analyses were carried out using 
SPSS software (SPSS version 21, SPSS Inc., Chicago, IL, USA).
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